Abstract
Background The introduction of the bacterium Wolbachia (wMel strain) into Aedes aegypti mosquitoes reduces their capacity to transmit dengue and other arboviruses. Evidence of a reduction in dengue case incidence following field releases of wMel-infected Ae. aegypti has been reported previously from a cluster randomised controlled trial in Indonesia, and quasi-experimental studies in Indonesia and northern Australia.
Methods Following a period of intensive community engagement, deployments of adult wMel-infected Ae. aegypti mosquitoes were conducted in Niterói, Brazil during 2017 – 2019. Deployments were phased across four release zones, with a total area of 83 km2 and a residential population of approximately 373,000. A quasi-experimental design was used to evaluate the effectiveness of wMel deployments in reducing dengue and chikungunya incidence. An untreated control zone was pre-defined, which was comparable to the intervention area in historical dengue trends. The wMel intervention effect was estimated by controlled interrupted time series analysis of monthly dengue and chikungunya case notifications to the public health surveillance system before, during and after releases, from release zones and the control zone.
Results Three years after commencement of releases, wMel introgression into local Ae. aegypti populations was heterogeneous throughout Niterói, reaching a high prevalence (>80%) in the earliest release zone, and more moderate levels (prevalence 40–70%) elsewhere. Despite this spatial heterogeneity in entomological outcomes, the wMel intervention was associated with a 69% reduction in dengue incidence (95% confidence interval 54%, 80%) and a 60% reduction in chikungunya incidence (95%CI 21%, 80%), in the aggregate release area compared with the pre-defined control area. This significant intervention effect on dengue was replicated across all four release zones, and in three of four zones for chikungunya.
Conclusions We demonstrate that wMel Wolbachia can be successfully introgressed into Ae. aegypti populations in a large and complex urban setting, and that a significant public health benefit from reduced incidence of dengue and chikungunya accrues even where the prevalence of wMel in local mosquito populations is moderate and spatially heterogeneous. These findings are consistent with the results of randomised and non-randomised field trials in Indonesia and northern Australia, and demonstrate the effectiveness of the Wolbachia biocontrol method as a multivalent intervention against both dengue and chikungunya.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://f1000research.com/articles/8-1328/v2
Funding Statement
This work was supported by the Brazilian Ministry of Health (DECIT/SVS), and a grant to Monash University from the Foundation for the National Institutes of Health through the Vector-Based Control of Transmission Discovery Research (VCTR) program of the Grand Challenges in Global Health Initiatives of the Bill and Melinda Gates Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approval to release Wolbachia-carrying Ae. aegypti mosquitoes into urban areas was obtained from three Brazilian governmental bodies: the National Agency of Sanitary Surveillance (ANVISA); the Ministry of Agriculture, Livestock and Supply (MAPA); and the Brazilian Institute of Environment and Renewable Natural Resources (IBAMA), which issued a Temporary Special Registry (Registro Especial Temporário (RET), nr. 0551716178/2017). Ethical approval was also obtained from the National Commission for Research Ethics (CONEP - CAAE 59175616.2.0000.0008).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data underlying the results presented in this study are publicly available at 10.6084/m9.figshare.13662203 (zone-level data) and 10.6084/m9.figshare.13662230 (neighbourhood-level data).
